The cost of multiple sclerosis drugs in the US and the pharmaceutical industry

Neurology

Volumn 84, Issue 21, 2015, Pages 2185-2192

  Hartung, Daniel M ^a   Bourdette, Dennis N ^b   Ahmed, Sharia M ^a   Whitham, Ruth H ^b  

^a OREGON STATE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; INTERFERON BETA SERINE; NATALIZUMAB; PRESCRIPTION DRUG; TERIFLUNOMIDE; TUMOR NECROSIS FACTOR INHIBITOR; IMMUNOLOGIC FACTOR; IMMUNOSUPPRESSIVE AGENT; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; COST BENEFIT ANALYSIS; DRUG COST; DRUG INDUSTRY; HUMAN; MULTIPLE SCLEROSIS; PHARMACEUTICAL CARE; PRIORITY JOURNAL; UNITED STATES; ANTAGONISTS AND INHIBITORS; COST; ECONOMICS;

COSTS AND COST ANALYSIS; DRUG INDUSTRY; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS; TUMOR NECROSIS FACTOR-ALPHA; UNITED STATES;

EID: 84929871469     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000001608     Document Type: Article

References (40)

1. IMS Health. Top Therapeutic Classes by Non-discounted Spending (U.S.). Available at: http://www.imshealth.com/deployedfiles/imshealth/Global/Content/Corporate/Press %20Room/2012-U.S/Top-Therapeutic-Classes-by-Non-Discounted-Spending.U.S.pdf. Accessed April 9, 2014.
2. Kobelt G, Berg J, Atherly D, Hadjimichael O. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology 2006;66:1696-1702.
3. FDB MedKnowledgeTM. San Francisco, CA: First Databank; 2014.
4. Pollack DA. Supreme Court to hear appeal of generic drug case. New York Times. April 1, 2014:B3.
5. Hauser SL, Johnston SC. Multiple sclerosis drugs: sticker shock. Ann Neurol 2012;71:A5-A6.
6. Bourdette D, Whitham R. Immunotherapy and multiple sclerosis: the devil is in the details. Neurology 2010;74: 1410-1411.
7. Goodin DS, Arnason BG, Coyle PK, Frohman EM, Paty DW. The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2003;61: 1332-1338.
8. AMCP guide to pharmaceutical payment methods, 2009 update (version 2.0). J Manag Care Pharm 2009;15:S3-S57, quiz S58-61.
9. Department of Health and Human Services, Office of the Inspector General. Medicaid Drug Price Comparison: Average Sales Price to Average Wholesale Price. Washington, DC: Department of Health and Human Services, Office of the Inspector General; 2005.
10. Bureau of Labor Statistics. Consumer Price Index Databases [online]. Available at: http://www.bls.gov/cpi/data. htm. Accessed November 11, 2013.
11. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther 2002; 27:299-309.
12. Wooldridge JM. Introductory Econometrics: A Modern Approach. Mason, OH: South-Western Cengage Learning; 2009.
13. British Medical Association and the Royal Pharmaceutical Society of Great Britain. British National Formulary, 66th ed. London: BMJ Publishing Group; 2013-2014.
14. Drug Benefit Prices (DBPs) for Products Reimbursed Under the Exceptional Access Program [online]. Available at: http://www.health.gov.on.ca/en/pro/programs/drugs/odbf/odbf-except-access.aspx. Accessed November 7, 2013.
15. Australian Department of Health. Pharmaceutical Benefits Scheme (PBS). Available at: http://www.pbs.gov.au/pbs/home. Accessed March 15, 2015.
16. Pharmacy Benefits Management Services [online]. Available at: http://www.pbm.va.gov/PBM/PharmaceuticalPrices.asp. Accessed August 11, 2014.
17. Medicaid Drug Price Comparisons: Average Manufacturer Price to Published Prices. Washington, DC: Department of Health and Human Services; 2005.
18. States' Collection of Rebates for Drugs Paid Through Medicaid Managed Care Organizations. Washington, DC: Department of Health and Human Services; 2012.
19. Donohue JM. The impact and evolution of Medicare Part D. N Engl J Med 2014;371:693-695.
20. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 2013;121:4439-4442.
21. Rogoff EG, Guirguis HS, Lipton RA, et al. The upward spiral of drug costs: a time series analysis of drugs used in the treatment of hemophilia. Thromb Haemost 2002;88: 545-553.
22. Guirguis HS, Rogoff EG. Strategies and impacts of new drug introduction: hemophilia treatment. J Health Care Finance 2004;31:1-12.
23. Guo J, Kelton CL, Pasquale M, et al. Price and marketshare competition of anti-ulcer gastric medications in the Ohio Medicaid market. Int J Pharm Med 2004; 18:271-282.
24. Lu ZJ, Comanor WS. Strategic pricing of new pharmaceuticals. Rev Econ Stat 1998;80:108-118.
25. Congressional Budget Office. How Increased Competition from Generic Drugs Has Affected Prices and Returns in the Pharmaceutical Industry. Washington, DC: US Government Printing Office; 1998.
26. Kohl H, Shrank WH. Increasing generic drug use in Medicare Part D: the role of government. J Am Geriatr Soc 2007;55:1106-1109.
27. Grabowski HG, Guha R, Salgado M. Regulatory and cost barriers are likely to limit biosimilar development and expected savings in the near future. Health Aff 2014;33: 1048-1057.
28. Relman AS, Angell M. America's other drug problem: how the drug industry distorts medicine and politics. New Repub 2002;227:27-41.
29. Kendall B. Teva Asks Supreme Court To Delay Possible Release of Generic Copaxone. Wall Street Journal. April 7, 2014. Available at: http://www.wsj.com/articles/SB10001424052702304819004579487430240670484. Accessed April 15, 2015.
30. Kesselheim AS, Avorn J. Biomedical patents and the public's health: is there a role for eminent domain? JAMA 2006;295:434-437.
31. Downing NS, Ross JS, Jackevicius CA, Krumholz HM. Avoidance of generic competition by Abbott Laboratories' fenofibrate franchise. Arch Intern Med 2012;172: 724-730.
32. Miller RM, Happe LE, Meyer KL, Spear RJ. Approaches to the management of agents used for the treatment of multiple sclerosis: consensus statements from a panel of U.S. managed care pharmacists and physicians. J Manag Care Pharm 2012;18:54-62.
33. Owens GM. Managed care aspects of managing multiple sclerosis. Am J Manag Care 2013;19:s307-312.
34. Brennan T, Shrank W. New expensive treatments for hepatitis C infection. JAMA 2014;312:593-594.
35. Bach PB. Limits on Medicare's ability to control rising spending on cancer drugs. N Engl J Med 2009;360: 626-633.
36. O'Sullivan BP, Orenstein DM, Milla CE. Pricing for orphan drugs: will the market bear what society cannot? JAMA 2013;310:1343-1344.
37. Yamamoto D, Campbell JD. Cost-effectiveness of multiple sclerosis disease-modifying therapies: a systematic review of the literature. Autoimmune Dis 2012;2012:784364.
38. Noyes K, Bajorska A, Chappel A, et al. Cost-effectiveness of disease-modifying therapy for multiple sclerosis: a population-based study. Neurology 2011;77:355-363.
39. Braithwaite RS, Meltzer DO, King JT Jr, Leslie D, Roberts MS. What does the value of modern medicine say about the $50, 000 per quality-adjusted life-year decision rule? Med Care 2008;46:349-356.
40. Goldberg LD, Edwards NC, Fincher C, Doan QV, Al-Sabbagh A, Meletiche DM. Comparing the costeffectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis. J Manag Care Pharm 2009;15:543-555.